Analyze Diet
Zygote (Cambridge, England)2002; 10(1); 37-45; doi: 10.1017/s096719940200206x

Suppression of meiosis by inhibitors of m-phase proteins in horse oocytes with low meiotic competence.

Abstract: Germinal vesicle (GV)-stage horse oocytes with diffuse chromatin are meiotically incompetent and degenerate in culture, whereas horse oocytes having condensed chromatin within the GV are meiotically competent. Degeneration of incompetent oocytes in culture may be related to premature GV breakdown, which could possibly be prevented by inhibition of m-phase protein activity. We examined the effects of 6-dimethylaminopurine (6-DMAP), butyrolactone and roscovitine on GV-stage horse oocytes. Culture in the presence of 2 mM 6-DMAP for 24 h suppressed meiosis (2% MI or MII compared with 38% for untreated oocytes). The proportion of GV-stage oocytes having condensed chromatin was not different between 6-DMAP culture and directly fixed controls; however, the proportion of oocytes with diffuse chromatin was significantly lower, and more oocytes with diffuse chromatin had atypical chromatin than did controls (p < 0.01). Culture with butyrolactone at 100 microM suppressed meiosis (5% MI + II). Again, this treatment maintained GV-stage oocytes having condensed chromatin, but the proportion of oocytes with diffuse chromatin was significantly reduced compared with directly fixed controls (p < 0.05). Culture with roscovitine at 25 microM was also effective in maintaining GV-stage oocytes having condensed chromatin; however, culture with 100 microM roscovitine did not suppress meiosis or maintain oocytes in the GV stage. These results indicate that meiosis in GV-stage horse oocytes having condensed chromatin may be suppressed by inhibitors of m-phase protein activity; however, oocytes originally having diffuse chromatin appear to degenerate in culture even in the presence of these inhibitors.
Publication Date: 2002-04-20 PubMed ID: 11964090DOI: 10.1017/s096719940200206xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article investigates how the activity of m-phase proteins influences the meiotic competence of horse oocytes – specifically, how certain inhibitors can suppress meiosis in those oocytes that initially have condensed chromatin, but not necessarily in oocytes that have diffuse chromatin.

Understanding Meiotic Competence

  • The competence of an oocyte for undergoing meiosis is determined by its chromatin configuration—the structure of its DNA and histone proteins.
  • In horse oocytes, those with condensed chromatin within the germinal vesicle (GV) are capable of undergoing meiosis, while those with diffuse chromatin are meiotically incompetent and tend to degenerate in culture.
  • However, the premature breakdown of the germinal vesicle in these incompetent oocytes could potentially be prevented by inhibiting the activity of m-phase proteins.

Effects of M-Phase Protein Inhibitors

  • In the study, the researchers evaluated the effects of three m-phase protein inhibitors, namely 6-dimethylaminopurine (6-DMAP), butyrolactone and roscovitine on GV-stage horse oocytes.
  • The results showed that when cultured in the presence of 2 mM 6-DMAP for 24 hours, the occurrences of meiosis were significantly suppressed.
  • While the proportion of GV-stage oocytes with condensed chromatin was found to be unaffected by the presence of 6-DMAP, the proportion of oocytes with diffuse chromatin was significantly lower. Notably, those with diffuse chromatin had atypical chromatin to a higher degree than control oocytes.

Further Evaluations and Results

  • The study further explored the effects of butyrolactone and roscovitine on the horse oocytes.
  • Results indicated that culture with butyrolactone at 100 microM also suppressed meiosis while maintaining GV-stage oocytes with condensed chromatin.
  • On the other hand, while roscovitine at 25 microM was efficient in sustaining GV-stage horse oocytes with condensed chromatin, culture with 100 microM roscovitine did not suppress meiosis or maintain oocytes in the GV stage.

Conclusions

  • The findings suggest that the process of meiosis in GV-stage horse oocytes having condensed chromatin can be suppressed by the inhibitors of m-phase protein activity.
  • However, for oocytes initially having diffuse chromatin, they appear to degenerate in the culture even in the presence of these inhibitors—a factor that sheds new light on the challenges related to the maintenance and preservation of oocyte integrity and function in the field of reproductive biology and medicine.

Cite This Article

APA
Hinrichs K, Love CC, Choi YH, Varner DD, Wiggins CN, Reinoehl C. (2002). Suppression of meiosis by inhibitors of m-phase proteins in horse oocytes with low meiotic competence. Zygote, 10(1), 37-45. https://doi.org/10.1017/s096719940200206x

Publication

ISSN: 0967-1994
NlmUniqueID: 9309124
Country: England
Language: English
Volume: 10
Issue: 1
Pages: 37-45

Researcher Affiliations

Hinrichs, Katrin
  • College of Veterinary Medicine, Texas A&M University, College Station 77843-4466, USA.
Love, Charles C
    Choi, Young Ho
      Varner, Dickson D
        Wiggins, C Nicole
          Reinoehl, Christina

            MeSH Terms

            • 4-Butyrolactone / analogs & derivatives
            • 4-Butyrolactone / pharmacology
            • Adenine / analogs & derivatives
            • Adenine / pharmacology
            • Animals
            • Chromatin / physiology
            • Dimethyl Sulfoxide / metabolism
            • Horses
            • Meiosis / drug effects
            • Meiosis / physiology
            • Oocytes / drug effects
            • Oocytes / physiology
            • Oogenesis / physiology
            • Purines / pharmacology
            • Roscovitine

            Citations

            This article has been cited 0 times.